Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA.
Biomark Med. 2012 Jun;6(3):339-48. doi: 10.2217/bmm.12.24.
While the most significant prognostic and predictive marker in the management of colorectal cancer patients is cancer cells in regional lymph nodes, approximately 30% of patients whose lymph nodes are ostensibly free of tumor cells by histopathology ultimately develop recurrent disease reflecting occult metastases. Molecular techniques utilizing highly specific markers and ultra-sensitive detection technologies have emerged as powerful staging platforms to establish prognosis and predict responsiveness to chemotherapy in colorectal cancer patients. This review describes the evolution of the tumor suppressor GUCY2C as a prognostic and predictive molecular biomarker that quantifies occult tumor burden in regional lymph nodes for staging patients with colorectal cancer.
虽然在结直肠癌患者的管理中，最显著的预后和预测标志物是区域淋巴结中的癌细胞，但大约 30%的患者在组织病理学上淋巴结表面无肿瘤细胞，但最终仍会出现复发疾病，这反映了隐匿性转移。利用高度特异性标志物和超灵敏检测技术的分子技术已成为建立结直肠癌患者预后和预测化疗反应的强大分期平台。本综述描述了肿瘤抑制因子 GUCY2C 的演变，作为一种预后和预测分子生物标志物，可定量评估结直肠癌患者区域淋巴结中的隐匿性肿瘤负担，用于分期。
